Ocular Therapeutix (NSDQ:OCUL) said today that the Centers for Medicare and Medicaid Services has assigned a specific and permanent reimbursement J-code for its Dextenza ophthalmic insert, which is approved for the treatment of ocular inflammation and pain following ophthalmic surgery.
The code assigned to Dextenza through the Healthcare Common Procedure Coding System will become effective on October 1, 2019.
Get the full story on our sister site, Drug Delivery Business.